Research Progress on the Mechanism of Action of Medicinal and Edible Homologous Substances in the Prevention and Treatment of Alzheimer's Disease

被引：0
|
作者：
Kang Y. [1 ]
Tang Y. [1 ]
Zhang D. [2 ]
Wang L. [2 ]
Wang X. [2 ]
Su Z. [2 ]
Yu H. [2 ]
机构：
[1] College of Traditional Chinese Pharmacy, Tianjin University of Traditional Chinese Medicine, Tianjin
[2] Tianjin Ubasio Biotechnology Group Co., Ltd., Tianjin
来源：
Science and Technology of Food Industry | 2024年 / 45卷 / 12期
关键词：
Alzheimer's disease; mechanism; medicinal and edible homologous substances;
D O I：
10.13386/j.issn1002-0306.2023090179
中图分类号：
学科分类号：
摘要：
Alzheimer's disease (AD) is a progressive neurodegenerative disease with insidious onset, commonly seen in the elderly and with increasing incidence, for which there is still no effective treatment. Medicinal and edible homologous substances refer to substances that are both food and traditional Chinese medicine, and have received widespread attention due to their safety and good therapeutic and health effects. This paper describes the pathogenesis of AD, and summarizes the anti-AD mechanism of medicinal and edible homologous substances from the aspects of slowing down the deposition of β-amyloid, inhibiting the over-phosphorylation of Tau protein, improving the cholinergic system, antioxidant, anti-inflammatory, and protection of neurons and synapses, so as to provide references for the development and application of medicinal and edible homologous substances products. © The Author(s) 2024.
引用
收藏
页码：18 / 27
页数：9
相关论文
共 100 条
  • [1] World Alzheimer Report 2019：Attitudes to dementia
  • [2] SONG Y, WANG J., Overview of Chinese research on senile dementia in mainland China[J], Ageing Research Reviews, 9, pp. S6-S12, (2010)
  • [3] DETURE M A, DICKSON D W., The neuropathological diagnosis of Alzheimer’s disease[J], Molecular Neurodegeneration, 14, 1, (2019)
  • [4] CALSOLARO V, EDISON P., Neuroinflammation in Alzheimer’s disease：Current evidence and future directions[J], Alzheimer’s & Dementia, 12, 6, pp. 719-732, (2016)
  • [5] BRIGGS C A, CHAKROBORTY S, STUTZMANN G E., Emerging pathways driving early synaptic pathology in Alzheimer’s disease[J], Biochemical and Biophysical Research Communications, 483, 4, pp. 988-997, (2017)
  • [6] SAVELIEFF M G, NAM G, KANG J, Et al., Development of multifunctional molecules as potential therapeutic candidates for Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis in the last decade[J], Chemical Reviews, 119, 2, pp. 1221-1322, (2019)
  • [7] DAS T K, JANA P, CHAKRABARTI S K, Et al., Curcumin downregulates GSK3 and Cdk5 in scopolamine-induced Alzheimer’s disease rats abrogating Aβ40/42 and Tau hyperphosphorylation[J], Journal of Alzheimer’s Disease Reports, 3, 1, pp. 257-267, (2019)
  • [8] GONZALEZ-GRANILLO A E, GNECCO D, DIAZ A, Et al., Curcumin induces cortico-hippocampal neuronal reshaping and memory improvements in aged mice[J], Journal of Chemical Neuroanatomy, 121, (2022)
  • [9] ZHANG H, SU Y, SUN Z, Et al., Ginsenoside Rg1 alleviates Aβ deposition by inhibiting NADPH oxidase 2 activation in APP/PS1 mice[J], Journal of Ginseng Research, 45, 6, pp. 665-675, (2021)
  • [10] YANG S D, YU H F, ZHANG L C, Et al., The effect of ginsenoside Rb1 on abnormal phosphory-lation of Tau induced by Aβ<sub>1-42</sub>[J], Natural Product Research and Development, 32, 7, pp. 1143-1147, (2020)
12345678910